163 related articles for article (PubMed ID: 38705935)
1. Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.
Ligumsky H; Amir S; Arbel Rubinstein T; Guion K; Scherf T; Karasik A; Wolf I; Rubinek T
Med Oncol; 2024 May; 41(6):138. PubMed ID: 38705935
[TBL] [Abstract][Full Text] [Related]
2. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
3. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
Miao XY; Gu ZY; Liu P; Hu Y; Li L; Gong YP; Shu H; Liu Y; Li CL
Peptides; 2013 Jan; 39():71-9. PubMed ID: 23116613
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
Li XN; Bu HM; Ma XH; Lu S; Zhao S; Cui YL; Sun J
Exp Clin Endocrinol Diabetes; 2017 Feb; 125(2):91-97. PubMed ID: 28008585
[No Abstract] [Full Text] [Related]
5. The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.
Andreozzi F; Raciti GA; Nigro C; Mannino GC; Procopio T; Davalli AM; Beguinot F; Sesti G; Miele C; Folli F
J Transl Med; 2016 Jul; 14(1):229. PubMed ID: 27473212
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway.
Yang S; Lin C; Zhuo X; Wang J; Rao S; Xu W; Cheng Y; Yang L
Am J Physiol Endocrinol Metab; 2020 Dec; 319(6):E1019-E1030. PubMed ID: 32985256
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.
Lee MY; Chen WC; Hsu WH; Chen SC; Lee JC
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540136
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Jojima T; Uchida K; Akimoto K; Tomotsune T; Yanagi K; Iijima T; Suzuki K; Kasai K; Aso Y
Atherosclerosis; 2017 Jun; 261():44-51. PubMed ID: 28445811
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway.
Xu WW; Guan MP; Zheng ZJ; Gao F; Zeng YM; Qin Y; Xue YM
Cell Physiol Biochem; 2014; 33(2):423-32. PubMed ID: 24556697
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
Owens DR; Monnier L; Bolli GB
Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
[TBL] [Abstract][Full Text] [Related]
11. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner.
Wei R; Ma S; Wang C; Ke J; Yang J; Li W; Liu Y; Hou W; Feng X; Wang G; Hong T
Am J Physiol Endocrinol Metab; 2016 Jun; 310(11):E947-57. PubMed ID: 27072494
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells.
Li Z; Ni CL; Yao Z; Chen LM; Niu WY
Metabolism; 2014 Aug; 63(8):1022-30. PubMed ID: 24972503
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism.
Krasner NM; Ido Y; Ruderman NB; Cacicedo JM
PLoS One; 2014; 9(5):e97554. PubMed ID: 24835252
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
Koehler JA; Kain T; Drucker DJ
Endocrinology; 2011 Sep; 152(9):3362-72. PubMed ID: 21771884
[TBL] [Abstract][Full Text] [Related]
15. The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions.
Miao X; Gu Z; Liu Y; Jin M; Lu Y; Gong Y; Li L; Li C
Peptides; 2018 Feb; 100():127-139. PubMed ID: 28712893
[TBL] [Abstract][Full Text] [Related]
16. Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
Kappe C; Zhang Q; Holst JJ; Nyström T; Sjöholm A
Am J Physiol Cell Physiol; 2013 Nov; 305(10):C1041-9. PubMed ID: 23986202
[TBL] [Abstract][Full Text] [Related]
17. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.
Wang J; Fan S; Xiong Q; Niu Y; Zhang X; Qin J; Shi Y; Zhang L
Acta Biochim Biophys Sin (Shanghai); 2021 Aug; 53(9):1189-1197. PubMed ID: 34357376
[TBL] [Abstract][Full Text] [Related]
19. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.
Burmeister MA; Ayala J; Drucker DJ; Ayala JE
Am J Physiol Endocrinol Metab; 2013 Apr; 304(7):E677-85. PubMed ID: 23341495
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.
Zhou Y; He X; Chen Y; Huang Y; Wu L; He J
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):394-9. PubMed ID: 26519882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
